

- Suzuki M. A Randomized Phase II/III Trial of 3 Weekly Intraperitoneal versus Intravenous Carboplatin in Combination with Intravenous Weekly Dose-Dense Paclitaxel for Newly Diagnosed Ovarian, Fallopian Tube and Primary Peritoneal Cancer. *Jpn J Clin Oncol.* 41(2):278-282, 2011
3. Konno R, Tamura S, Dobbelaere K, Yoshikawa H. Prevalence and type distribution of human papillomavirus in healthy Japanese women aged 20 to 25 years old enrolled in a clinical study. *Cancer Sci*, 102(4):877-882, 2011
 4. Matsumoto K, Oki A, Furuta R, Maeda H, Yasugi T, Takatsuka N, Mitsuhashi A, Fuji T, Hirai Y, Iwasaka T, Yaegashi N, Watanabe Y, Nagai Y, Kitagawa T, Yoshikawa H. Predicting the Progression of Cervical Precursor Lesions by Human Papillomavirus Genotyping: A Prospective Cohort Study. *Int J Cancer*, 128(12): 2898-2910, 2011.
 5. Tanaka YO, Okada S, Satoh T, Matsumoto K, Oki A, Nishida M, Yoshikawa H, Saida T, Minami M. Ovarian serous surface papillary borderline tumors form sea anemone-like masses. *J Magn Reson Imaging.* 33(3):633-640, 2011.
 6. Onda T, Yoshikawa H. Neoadjuvant chemotherapy for advanced ovarian cancer: overview of outcomes and unanswered questions. *Expert Review of Anticancer Therapy*, 11(7): 1055-1069, 2011.
 7. Nakamura E, Satoh T, Iwakawa M, Nakawatari M, Oki A, Matsumoto K, Okada S, Minaguchi T, Yoshikawa H, Imai T. Villin1, a diagnostic marker for endometrial adenocarcinoma with high grade nuclear atypia. *Cancer Biology & Therapy*, 12(3):181-190, 2011.
 8. Onda T, Konishi I, Yoshikawa H, Kamura T. The History of the Gynecologic Cancer Study Group (GCSG) of the Japan Clinical Oncology Group (JCOG). *Jpn J Clin Oncol*, 41(10): 1156-1161, 2011.
 9. Tanaka YO, Okada S, Satoh T, Matsumoto K, Saida T, Oki A, Yoshikawa H, Minami M. Solid

- non-invasive ovarian masses on MR: Histopathology and a diagnostic approach. *Eur J Radiol.* 80(2): e91-e97, 2011.
10. Matsumoto K, Hirai Y, Furuta R, Takatsuka N, Oki A, Yasugi T, Maeda H, Mitsuhashi A, Fuji T, Kawana K, Iwasaka T, Yaegashi N, Watanabe Y, Nagai Y, Kitagawa T, Yoshikawa H. Subsequent risks for cervical precancer and cancer in women with low-grade squamous intraepithelial lesions unconfirmed by colposcopy-directed biopsy: results from a multicenter, prospective, cohort study. *Int J Clin Oncol*, in press
 11. Inamine M, Nagai Y, Mitsuhashi A, Nagase S, Yaegashi N, Yoshikawa H, Aoki Y. Cigarette smoke stimulates VEGF-C expression in cervical intraepithelial neoplasia (CIN) 1 and 2 lesions. *Int J Clin Oncol*, in press
 12. Matsumoto K, Maeda H, Oki A, Takatsuka N, Yasugi T, Furuta R, Hirata R, Mitsuhashi A, Fuji T, Hirai Y, Iwasaka T, Yaegashi N, Watanabe Y, Nagai Y, Kitagawa T, Yoshikawa H. HLA Class II DRB1*1302 1 allele protects against progression to cervical intraepithelial neoplasia grade 3: A multicenter, prospective, cohort study. *Int J Gynecol Cancer*, in press
 13. Ochi H, Matsumoto K, Kondo K, Oki A, Furuta R, Hirai Y, Yasugi T, Takatsuka N, Maeda H, Mitsuhashi A, Fuji T, Kawana K, Iwasaka T, Yaegashi N, Watanabe Y, Nagai Y, Kitagawa T, Kanda T, Yoshikawa H. Do neutralizing antibody responses generated by human papillomavirus infections favor a better outcome of low-grade cervical lesions? *J Med Virol*, 2012 in press
 14. Michikami H, Minaguchi T, Ochi H, Onuki M, Okada S, Matsumoto K, Satoh T, Oki A, Yoshikawa H. Safety and efficacy of substituting nedaplatin after carboplatin hypersensitivity reactions in gynecologic malignancies. *J Obstet Gynecol Res*, in press
 15. Kitagawa R, Katsumata N, Ando M, Shimizu C, Fujiwara Y, Yoshikawa H, Satoh T, Nakanishi T, Ushijima K, Kamura T. A multi-institutional

- phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer. *Gynecol. Oncol.* in press.
16. Fujiwara K, Aotani E, Hamano T, Nagao S, Yoshikawa H, Sugiyama T, Kigawa J, Aoki D, Katsumata N, Takeuchi M, Suzuki M: A Randomized Phase II/III Trial of 3 Weekly Intraperitoneal versus Intravenous Carboplatin in Combination with Intravenous Weekly Dose-Dense Paclitaxel for Newly Diagnosed Ovarian, Fallopian Tube and Primary Peritoneal Cancer. *Jpn J Clin Oncol.* 2010 Oct 11. [Epub ahead of print]
 17. Nagase S, Katabuchi H, Hiura M, Sakuragi N, Aoki Y, Kigawa J, Saito T, Hachisuga T, Ito K, Uno T, Katsumata N, Komiyama S, Susumu N, Emoto M, Kobayashi H, Metoki H, Konishi I, Ochiai K, Mikami M, Sugiyama T, Mukai M, Sagae S, Hoshiai H, Aoki D, Ohmichi M, Yoshikawa H, Iwasaka T, Udagawa Y, Yaegashi N. Evidence-based guidelines for treatment of uterine body neoplasm in Japan: Japan Society of Gynecologic Oncology (JSGO) 2009 edition. *Int J Clin Oncol.* 2010 Nov 11. [Epub ahead of print]
 18. Fujiwara K, Aotani E, Hamano T, Nagao S, Yoshikawa H, Sugiyama T, Kigawa J, Aoki D, Katsumata N, Takeuchi M, Suzuki M. A Randomized Phase II/III Trial of 3 Weekly Intraperitoneal versus Intravenous Carboplatin in Combination with Intravenous Weekly Dose-Dense Paclitaxel for Newly Diagnosed Ovarian, Fallopian Tube and Primary Peritoneal Cancer. *Jpn J Clin Oncol.* 2010 Oct 11. [Epub ahead of print]
 19. Matsumoto K, Oki A, Furuta R, Maeda H, Yasugi T, Takatsuka N, Mitsuhashi A, Fujii T, Hirai Y, Iwasaka T, Yaegashi N, Watanabe Y, Nagai Y, Kitagawa T, Yoshikawa H. Predicting the Progression of Cervical Precursor Lesions by Human Papillomavirus Genotyping: A Prospective Cohort Study. *Int J Cancer,* 2010 Aug 23. [Epub ahead of print]
 20. Tanaka YO, Okada S, Satoh T, Matsumoto K, Saida T, Oki A, Yoshikawa H, Minami M. Solid

- non-invasive ovarian masses on MR: Histopathology and a diagnostic approach. *Eur J Radiol.* 2010 Jun 22. [Epub ahead of print]
21. Matsumoto K, Oki A, Furuta R, Maeda H, Yasugi T, Takatsuka N, Mitsunashi A, Fujii T, Hirai Y, Iwasaka T, Yaegashi N, Watanabe Y, Nagai Y, Kitagawa T, Yoshikawa H. Tobacco Smoking and Regression of Low-Grade Cervical Abnormalities. *Cancer Sciences*, 2010, 101(9): 2065-2073.
 22. Konno R, Sagae S, Yoshikawa H, Basu PS, Hanley SJ, Tan JH, Shin HR. Cervical Cancer Working Group report. *Jpn J Clin Oncol.* 2010,40 Suppl 1:i44-50,
 23. Saida T, Tanaka YO, Ohara K, Oki A, Sato T, Yoshikawa H, Minami M. Can MRI predict local control rate of uterine cervical cancer immediately after radiation therapy? *Magn Reson Med Sci.* 2010,9(3):141-148.
 24. Konno R, Tamura S, Dobbelaere K, Yoshikawa H. Efficacy of Human Papillomavirus Type 16/18 AS04-Adjuvanted Vaccine in Japanese Women Aged 20 to 25 Years: Final Analysis of a Phase 2 Double-Blind, Randomized Controlled Trial. *Int J Gynecol Cancer.* 2010, 20(5):847-855.
 25. Matsumoto K, Oki A, Satoh T, Okada S, Minaguchi T, Onuki M, Ochi H, Nakao S, Sakurai M, Abe A, Hamada H, Yoshikawa H. Interleukin-10 -1082 gene polymorphism and susceptibility to Cervical Cancer among Japanese Women. *Jpn J Clin Oncol.* 2010,40(11): 1113-1116.
 26. Konno R, Tamura S, Dobbelaere K, Yoshikawa H. Efficacy of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double-blind, randomized, controlled trial. *Int J Gynecol Cancer* 2010,20(3): 404-410.
 27. Nagase S, Inoue Y, Umesaki N, Aoki D, Ueda M, Sakamoto H, Kobayashi S, Kitagawa R, Toita T, Nagao S, Hasegawa K, Fukasawa I, Fujiwara K, Watanabe Y, Ito K, Niikura H, Iwasaka T, Ochiai K, Katabuchi

- H, Kamura T, Konishi I, Sakuragi N, Tanaka T, Hirai Y, Hiramatsu Y, Mukai M, Yoshikawa H, Takano T, Yoshinaga K, Otsuki T, Sakuma M, Inaba N, Udagawa Y, Yaegashi N. Evidence-based guidelines for treatment of cervical cancer in Japan: Japan Society of Gynecologic Oncology (JSGO) 2007 edition. *Int J Clin Oncol.* 2010,15(2):117-124.
28. Nagano M, Kimura K, Yamashita T, Ohneda K, Nozawa D, Hamada H, Yoshikawa H, Ochiai N, Ohneda O. Hypoxia responsive mesenchymal stem cells derived from human umbilical cord blood are effective for bone repair. *Stem Cells Dev.* 2010,19(8):1195-1210.
29. Tanaka YO, Okada S, Yagi T, Satoh T, Oki A, Tsunoda H, Yoshikawa H. MRI of endometriotic cysts in association with ovarian carcinoma. *Am J Roentgenol.* 2010, 194(2):355-361.
30. Satoh T, Hatae M, Watanabe Y, Yaegashi N, Ishiko O, Kodama S, Yamaguchi S, Ochiai K, Takano M, Yokota H, Kawakami Y, Nishimura S, Ogishima D, Nakagawa S, Kobayashi H, Shiozawa T, Nakanishi T, Kamura T, Konishi I, and Yoshikawa H. Outcomes of Fertility-Sparing Surgery for Stage I Epithelial Ovarian Cancer: A Proposal for Patient Selection. *J Clin Oncol.* 2010,28(10):1727-1732.
31. Saito I, Kitagawa R, Fukuda H, Shibata T, Katsumata N, Konishi I, Yoshikawa H, Kamura T. A Phase III Trial of Paclitaxel plus Carboplatin Versus Paclitaxel plus Cisplatin in Stage IVB, Persistent or Recurrent Cervical Cancer: Gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505). *Jpn J Clin Oncol.* 2010,40(1): 90-93.
32. Onda T, Yoshikawa H, Yasugi T, Matsumoto K and Taketani Y. The Optimal Debulking After Neoadjuvant Chemotherapy in Ovarian Cancer; Proposal Based on Interval Look During Upfront Surgery Setting Treatment. *Jpn J Clin Oncol.* 2010,40(1): 36-41.
33. Onda T, Kobayashi H, Nakanishi T, Hatae M, Iwasaka T, Konishi I, Shibata T, Fukuda H, Kamura T,

- Yoshikawa H. Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206, Gynecol. Oncol.2009;113(1):57-62.
34. Konno R, Dobbelaere K O, Godeaux O O, Tamura S, Yoshikawa H. Immunogenicity, reactogenicity and safety of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women: interim analysis of a phase II double-blind, randomized controlled trial at Month 7. Int J Gynecol Cancer.2009;19(5):905-911.
35. Abe K, Shimizu R, Pan X, Hamada H, Yoshikawa H, Yamamoto M. Stem cells of GATA1-related leukemia undergo pernicious changes after 5-fluorouracil treatment. Experimental Hematology.2009;37(4):435-445.
36. Tanaka YO, Tsunoda H, Sugano M, Satoh T, Yagi H, Minami R, Shiigai M, Inadome Y, Yoshikawa H, Noguchi M, Minami M. MR and CT findings of leiomyomatosis peritonealis disseminata with emphasis on assisted reproductive technology as a risk factor. Br J Radiol.2009;82(975):e44-47.
37. Onuki M, Matsumoto K, Satoh T, Oki A, Okada S, Minaguchi T, Ochi H, Nakao S, Someya K, Yamada N, Hamada H, Yoshikawa H. Human papillomavirus infections among Japanese women: age-related prevalence and type-specific risk for cervical cancer. Cancer Sciences.2009;100(7):1312-1316.
38. Onda T, Yoshikawa H. A phase III randomized trial comparing neoadjuvant chemotherapy and upfront debulking surgery is indispensable as a basis for changing the standard treatment of advanced Müllerian cancer. Gynecol Oncol. in press.
39. Onda T, Yoshikawa H, Yasugi T, Matsumoto K and Taketani Y. The Optimal Debulking After Neoadjuvant Chemotherapy in Ovarian Cancer: Proposal Based on Interval Look During Upfront Surgery Setting Treatment. Jpn J Clin Oncol. in press.

40. Kondo K, Ishii Y, Mori S, Shimabukuro S, Yoshikawa H, Kanda T. Nuclear location of minor capsid protein L2 is required for expression of a reporter plasmid packaged in HPV51 pseudovirions. *Virology*. in press.
41. Saito I, Kitagawa R, Fukuda H, Shibata T, Katsumata N, Konishi I, Yoshikawa H, Kamura T. A Phase III Trial of Paclitaxel plus Carboplatin Versus Paclitaxel plus Cisplatin in Stage IVB, Persistent or Recurrent Cervical Cancer: Gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505). *Jpn J Clin Oncol*. in press.
42. Satoh T, Hatae M, Watanabe Y, Yaegashi N, Ishiko O, Kodama S, Yamaguchi S, Ochiai K, Takano M, Yokota H, Kawakami Y, Nishimura S, Ogishima D, Nakagawa S, Kobayashi H, Shiozawa T, Nakanishi T, Kamura T, Konishi I, Yoshikawa H. Outcomes of Fertility-Sparing Surgery for Stage I Epithelial Ovarian Cancer: A Proposal for Patient Selection. *JCO*. in press.
- (分担研究者：青木大輔)
1. Nomura H, Tsuda H, Kataoka F, Chiyoda T, Yamagami W, Tominaga E, Susumu N, Aoki D: Retrospective study comparing irinotecan and pegylated liposomal doxorubicin in treatment of recurrent platinum-refractory/resistant epithelial ovarian cancer. *Eur J Gynaec Oncol*, 33(1): 86-89, 2012
 2. Fujiwara K, Aotani E, Hamano T, Nagao S, Yoshikawa H, Sugiyama T, Kigawa J, Aoki D, Katsumata N, Takeuchi M, Suzuki M: A Randomized Phase II/III Trial of 3 Weekly Intraperitoneal versus Intravenous Carboplatin in Combination with Intravenous Weekly Dose-Dense Paclitaxel for Newly Diagnosed Ovarian, Fallopian Tube and Primary Peritoneal Cancer. *Jpn J Clin Oncol*. 2010 Oct 11. [Epub ahead of print]
 3. Aoki D, Katsumata N, Nakanishi T, Kigawa J, Fujiwara K, Takehara K, Kamiura S, Hiura M, Hatae M, Sugiyama T, Ochiai K, Noda K: A Phase II Clinical Trial of Topotecan in Japanese Patients with Relapsed Ovarian Carcinoma. *Jpn J Clin Oncol*,

2010.

Nat Genet, 2010, 42: 707-710

4. Nomura H, Aoki D, Takahashi F, Katsumata N, Watanabe Y, Konishi I, Jobo T, Hatae M, Hiura M, Yaegashi N: Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041). *Ann Oncol*, 2010.
5. Chiyoda T, Tsuda H, Nomura H, Kataoka F, Tominaga E, Suzuki A, Susumu N, Aoki D: Effects of third-line chemotherapy for women with recurrent ovarian cancer who received platinum/taxane regimens as first-line chemotherapy. *Eur J Gynaecol Oncol*, 2010, 31: 364-368
6. Uno S, Zembutsu H, Hirasawa A, Takahashi A, Kubo M, Akahane T, Aoki D, Kamatani N, Hirata K, Nakamura Y: A genome-wide association study identifies genetic variants in the CDKN2BAS locus associated with endometriosis in Japanese. *Nat Genet*, 2010, 42: 707-710
7. Tominaga E, Tsuda H, Arao T, Nishimura S, Takano M, Kataoka F, Nomura H, Hirasawa A, Aoki D, Nishio K: Amplification of GNAS may be an independent, qualitative, and reproducible biomarker to predict progression-free survival in epithelial ovarian cancer. *Gynecol Oncol*, 2010, 118: 160-166
8. Nomura H, Tsuda H, Susumu N, Fujii T, Banno K, Kataoka F, Tominaga E, Suzuki A, Chiyoda T, Aoki D: Lymph node metastasis in grossly apparent stages I and II epithelial ovarian cancer. *Int J Gynecol Cancer*, 2010, 20: 341-345
9. Nagase S, Inoue Y, Umesaki N, Aoki D, Ueda M, Sakamoto H, Kobayashi S, Kitagawa R, Toita T, Nagao S, Hasegawa K, Fukasawa I, Fujiwara K, Watanabe Y, Ito K, Niikura H, Iwasaka T, Ochiai K, Katabuchi H, Kamura T, Konishi I, Sakuragi N, Tanaka T, Hirai Y, Hiramatsu Y, Mukai M, Yoshikawa H, Takano T, Yoshinaga K, Otsuki T, Sakuma M, Inaba N, Udagawa Y,

- Yaegashi N: Evidence-based guidelines for treatment of cervical cancer in Japan: Japan Society of Gynecologic Oncology (JSGO) 2007 edition. *Int J Clin Oncol*, 2010, 15: 117-124
10. Takakura S, Takano M, Takahashi F, Saito T, Aoki D, Inaba N, Noda K, Sugiyama T, Ochiai K: Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study. *Int J Gynecol Cancer*, 2010, 20: 240-247
11. Nishimura S, Ito YM, Tsuda H, Ohnishi Y, Kataoka F, Nomura H, Chiyoda T, Suzuki A, Susumu N, Aoki D, Hatae M. The sensitivity and specificity of a new formula to distinguish endometrioid type endometrial carcinoma from ovarian endometrial carcinoma. *Eur J Obstet Gynecol Reprod Biol*.2009:Epub ahead of print.
12. Seko A, Kataoka F, Aoki D, Sakamoto M, Nakamura T, Hatae M, Yonezawa S, Yamashita K. N-Acetylglucosamine 6-O-sulfotransferase-2 as a tumor marker for uterine cervical and corpus cancer. *Glycoconj J*. 2009:Epub ahead of print.
13. Kawaguchi M, Banno K, Yanokura M, Kobayashi Y, Kishimi A, Ogawa S, Kisu I, Nomura H, Hirasawa A, Susumu N, Aoki D. Analysis of candidate target genes for mononucleotide repeat mutation in microsatellite instability-high (MSI-H) endometrial cancer. *Int J Oncol*.2009;35:977-982.
14. Muraki Y, Banno K, Yanokura M, Kobayashi Y, Kawaguchi M, Nomura H, Hirasawa A, Susumu N, Aoki D. Epigenetic DNA hypermethylation: clinical applications in endometrial cancer (Review). *Oncol Rep*.2009;22:967-972.
15. Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, Ochiai K, Noda K. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.

- Lancet.2009;374:1331-1338.
16. Watanabe Y, Kitagawa R, Aoki D, Takeuchi S, Sagae S, Sakuragi N, Yaegashi N. Practice pattern for postoperative management of endometrial cancer in Japan: a survey of the Japanese Gynecologic Oncology Group. *Gynecol Oncol*.2009;115:456-459.
 17. Nishio H, Fujii T, Kameyama K, Susumu N, Nakamura M, Iwata T, Aoki D. Abdominal radical trachelectomy as a fertility-sparing procedure in women with early-stage cervical cancer in a series of 61 women. *Gynecol Oncol*.2009;115:51-55.
 18. Kawaguchi M, Yanokura M, Banno K, Kobayashi Y, Kuwabara Y, Kobayashi M, Nomura H, Hirasawa A, Susumu N, Aoki D. Analysis of a correlation between the BRAF V600E mutation and abnormal DNA mismatch repair in patients with sporadic endometrial cancer. *Int J Oncol*.2009;34:1541-7.
 19. Aoki D, Watanabe Y, Jobo T, Ushijima K, Hasegawa K, Susumu N, Suzuki N, Aoki R, Isonishi S, Sagae S, Ishizuka B, Kamura T, Udagawa Y, Hoshiai H, Ohashi Y, Ochiai K, Noda K. Favourable prognosis with modified dosing of docetaxel and cisplatin in Japanese patients with ovarian cancer. *Anticancer Res*.2009;29:561-6.
 20. Aoki D, Oda Y, Hattori S, Taguchi K, Ohishi Y, Basaki Y, Oie S, Suzuki N, Kono S, Tsuneyoshi M, Ono M, Yanagawa T, Kuwano M. Overexpression of class III beta-tubulin predicts good response to taxane-based chemotherapy in ovarian clear cell adenocarcinoma. *Clin Cancer Res*.2009;15:1473-80.
 21. Seko A, Kataoka F, Aoki D, Sakamoto M, Nakamura T, Hatae M, Yonezawa S, Yamashita K. Beta1,3-galactosyltransferases-4/5 are novel tumor markers for gynecological cancers. *Tumour Biol*.2009;30:43-50.
 22. 青木大輔. 1 各種のがん 8)女性子宮体がん(子宮内膜がん). がん診療 update 日本医師会雑誌 第138巻・特別号(1)生涯教育シリーズ76(監修 跡見裕 編集 島田安博, 杉原健一, 谷本光音, 吉村典).2009:258-261, 日本医師会.東京.

23. 片岡史夫, 青木大輔. II. 各論
8.CA130.腫瘍マーカーハンドブック
改訂版(編者:石井 勝).2009 :53-56,
医薬ジャーナル社. 大阪.
24. 野村弘行, 青木大輔. 第2章 子宮
体癌 1)術後補助化学療法. 婦人科
癌化学療法ポケットマニュアル(監修
野田起一郎) :34-44,メディカルレビ
ュー社. 東京. 2009.
- (分担研究者:勝俣範之)
1. Kitagawa.R, Katsumata.N,
Ando.M, Shimizu.C, Fujiwara.Y,
Yoshikawa.H, Satoh.T,
Nakanishi.T, Ushijima.K,
Kamura.T. A multi-institutional
phase II trial of paclitaxel and
carboplatin in the treatment of
advanced or recurrent cervical
cancer. *Gynecol Oncol*. 2012 Feb
12. [Epub ahead of print]
2. Matsumoto.K, Katsumata.N,
Saito.I, Shibata.T, Konishi.I,
Fukuda.H, Kamura.T. Phase II
Study of Oral Etoposide and
Intravenous Irinotecan for
Patients with
Platinum-resistant and
Taxane-pretreated Ovarian
Cancer . Japan Clinical
Oncology Group Study 0503.
Jpn J Clin Oncol. 2012 Feb 9.
[Epub ahead of print]
3. Ando.M, Yonemori.K,
Katsumata.N, Shimizu.C,
Hirata.T, Yamamoto.H,
Hashimoto.K, Yunokawa.M,
Tamura.K, Fujiwara.Y. Phase I
and pharmacokinetic study of
nab-paclitaxel, nanoparticle
albumin-bound paclitaxel,
administered weekly to
Japanese patients with solid
tumors and metastatic breast
cancer. *Cancer Chemother
Pharmacol*. 2012
Feb;69(2):457-65
4. Tanabe.Y, Hashimoto.K,
Shimizu.C, Hirakawa.A,
Harano.K, Yunokawa.M,
Yonemori.K, Katsumata.N,
Tamura.K, Ando.M, Kinoshita.T,
Fujiwara.Y. 2012
Feb;69(2):457-65.
5. Hashimoto.K, Yonemori.K,
Katsumata.N, Hirakawa.A,
Hirata.T, Yamamoto.H,
Shimizu.C, Tamura.K, Ando.M,
Fujiwara.Y. Use of squamous
cell carcinoma antigen as a
biomarker of chemotherapy
response in patients with
metastatic cervical carcinoma.
*Eur J Obstet Gynecol Reprod
Biol*. 2011 Dec;159(2):394-8.

6. Ono M, Ando M, Yonemori K, Yamamoto H, Hirata T, Shimizu C, Tamura K, Katsumata N, Fujiwara Y. Second-line chemotherapy in patients with primary unknown cancer. *J Cancer Res Clin Oncol*. 2011 Aug;137(8):1185-91.
7. Yonemori K, Hirakawa A, Ando M, Hirata T, Yunokawa M, Shimizu C, Katsumata. N, Tamura K, Fujiwara Y. The notorious "drug lag" for oncology drugs in Japan. *Invest New Drugs*. 2011 Aug;29(4):706-12.
8. Tanioka M, Katsumata. N, Yonemori K, Kouno T, Shimizu C, Tamura K, Ando M, Fujiwara Y. Second platinum therapy in patients with uterine cervical cancer previously treated with platinum chemotherapy. *Cancer Chemother Pharmacol*. 2011 Aug;68(2):337-42.
9. Tamura K, Shimizu C, Hojo T, Akashi-Tanaka S, Kinoshita T, Yonemori K, Kouno T, Katsumata. N, Ando M, Aogi K, Koizumi F, Nishio K, Fujiwara Y. FcyR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. *Ann Oncol*. 2011 Jun;22(6):1302-7.
10. Katsumata. N, Hirai Y, Kamiura S, Sugiyama T, Kokawa K, Hatae M, Nishimura R, Ochiai K. Phase II study of S-1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer. *Ann Oncol*. 2011 Jun;22(6):1353-7.
11. Yonemori K, Hirakawa A, Ando M, Hirata T, Shimizu C, Katsumata. N, Tamura K, Fujiwara Y. Compliance with Good Clinical Practice in oncology registration trials in Japan. *Ann Oncol*. 2011 Jun;22(6):1451-6.
12. Hirata T, Yonemori K, Hirakawa A, Shimizu C, Tamura K, Ando M, Katsumata. N, Tanimoto M, Fujiwara Y. Efficacy of pleurodesis for malignant pleural effusions in breast cancer patients. *Eur Respir J*. 2011 May 12.

13. Ono M, Tsuda H, Shimizu C, Yamamoto S, Shibata T, Yamamoto H, Hirata T, Yonemori K, Ando M, Tamura K, Katsumata N, Kinoshita T, Takiguchi Y, Tanzawa H, Fujiwara Y. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. *Breast Cancer Res Treat.* 2011 May 12.
14. Katsumata N. Dose-dense therapy is of benefit in primary treatment of ovarian cancer? In favor *Ann Oncol* (2011) 22(Suppl 8): viii29-viii32
15. Fujiwara K, Aotani E, Hamano T, Nagao S, Yoshikawa H, Sugiyama T, Kigawa J, Aoki D, Katsumata N, Takeuchi M, Suzuki M: A Randomized Phase II/III Trial of 3 Weekly Intraperitoneal versus Intravenous Carboplatin in Combination with Intravenous Weekly Dose-Dense Paclitaxel for Newly Diagnosed Ovarian, Fallopian Tube and Primary Peritoneal Cancer. *Jpn J Clin Oncol.* 2010 Oct 11. [Epub ahead of print]
16. Noriyuki Katsumata Dose-dense paclitaxel for advanced ovarian cancer - Authors' reply. *Lancet* 2010;375:281
17. Saito I, Kitagawa R, Fukuda H, Shibata T, Katsumata N, Konishi I, Yoshikawa H, Kamura T. A Phase III Trial of Paclitaxel plus Carboplatin Versus Paclitaxel plus Cisplatin in Stage IVB, Persistent or Recurrent Cervical Cancer: Gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505). *Jpn J Clin Oncol.* 40(1): 90-93, 2010
18. Tamura K, Shimizu C, Hojo T, Akashi-Tanaka S, Kinoshita T, Yonemori K, Kouno T, Katsumata N, Ando M, Aogi K, Koizumi F, Nishio K, Fujiwara Y. Fc{gamma}R2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. *Ann Oncol.* 2010 [Epub ahead of print]
19. Nagase S, Katabuchi H, Hiura M, Sakuragi N, Aoki Y, Kigawa J, Saito T, Hachisuga T, Ito K, Uno T, Katsumata N,

- Komiyama S, Susumu N, Emoto M, Kobayashi H, Metoki H, Konishi I, Ochiai K, Mikami M, Sugiyama T, Mukai M, Sagae S, Hoshiai H, Aoki D, Ohmichi M, Yoshikawa H, Iwasaka T, Udagawa Y, Yaegashi N. Evidence-based guidelines for treatment of uterine body neoplasm in Japan: Japan Society of Gynecologic Oncology (JSGO) 2009 edition. *Int J Clin Oncol*. 2010 Nov 11. [Epub ahead of print]
20. Tanioka M, Katsumata N, Yonemori K, Kouno T, Shimizu C, Tamura K, Ando M, Fujiwara Y. Second platinum therapy in patients with uterine cervical cancer previously treated with platinum chemotherapy. *Cancer Chemother Pharmacol*. 2010 [Epub ahead of print]
21. Aoki D, Katsumata N, Nakanishi T, Kigawa J, Fujiwara K, Takehara K, Kamiura S, Hiura M, Hatae M, Sugiyama T, Ochiai K, Noda K. A Phase II Clinical Trial of Topotecan in Japanese Patients with Relapsed Ovarian Carcinoma. *Jpn J Clin Oncol*. 2010 Oct 25. [Epub ahead of print]
22. Fujiwara K, Aotani E, Hamano T, Nagao S, Yoshikawa H, Sugiyama T, Kigawa J, Aoki D, Katsumata N, Takeuchi M, Suzuki M. A Randomized Phase II/III Trial of 3 Weekly Intraperitoneal versus Intravenous Carboplatin in Combination with Intravenous Weekly Dose-Dense Paclitaxel for Newly Diagnosed Ovarian, Fallopian Tube and Primary Peritoneal Cancer. *Jpn J Clin Oncol*. 2010 Oct 11. [Epub ahead of print]
23. Takahashi T, Hoshi E, Takagi M, Katsumata N, Kawahara M, Eguchi K. Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin. *Cancer Sci*. 2010 Nov;101(11):2455-61.
24. Nomura H, Aoki D, Takahashi F, Katsumata N, Watanabe Y, Konishi I, Jobo T, Hatae M, Hiura M, Yaegashi N. Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a

- Japanese Gynecologic Oncology Group study (JGOG2041). *Ann Oncol.* 2010 Aug 9. [Epub ahead of print]
25. Tanioka M, Shimizu C, Yonemori K, Yoshimura K, Tamura K, Kouno T, Ando M, Katsumata N, Tsuda H, Kinoshita T, Fujiwara Y. Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy. *Br J Cancer.* 2010 Jul 27;103(3):297-302.
26. Hashimoto K, Fujimoto H, Kouno T, Koseki M, Yonemori K, Hirata T, Yunokawa M, Shimizu C, Katsumata N, Tamura K, Ando M, Takeuchi M, Nakanishi H, Komiyama M, Nakagawa T, Fujiwara Y. The incidence and management of metachronous testicular germ cell tumors in patients with extragonadal germ cell tumors. *Urol Oncol.* 2010 May 14. [Epub ahead of print]
27. Hashimoto K, Yonemori K, Katsumata N, Shimizu C, Hirakawa A, Hirata T, Kouno T, Tamura K, Ando M, Fujiwara Y. Prediction of progressive disease using tumor markers in metastatic breast cancer patients without target lesions in first-line chemotherapy. *Ann Oncol.* 2010 Nov;21(11):2195-200.
28. Hashimoto K, Yonemori K, Shimizu C, Hirakawa A, Yamamoto H, Ono M, Hirata T, Kouno T, Tamura K, Katsumata N, Ando M, Fujiwara Y. A retrospective study of the impact of age on patterns of care for elderly patients with metastatic breast cancer. *Med Oncol.* 2010 Mar 31. [Epub ahead of print]
29. Yonemori K, Kouno T, Ando M, Hirakawa A, Yamamoto H, Ono M, Hirata T, Shimizu C, Tamura K, Katsumata N, Fujiwara Y. Influence of suboptimal treatment in patients with mediastinal primary nonseminomatous germ cell tumors. *Oncology.* 2010;78(1):34-9. Epub 2010 Feb
30. Yonemori K, Tsuta K, Shimizu C, Hatanaka Y, Hirakawa A, Ono M, Kouno T, Katsumata N, Ando M, Tamura K, Hasegawa T, Kinoshita T, Fujiwara Y. Immunohistochemical expression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with

- trastuzumab-containing
neoadjuvant chemotherapy. J Surg Oncol. 2010 Mar 1;101(3):222-7.
31. Tanioka M, Katsumata N, Sasajima Y, Ikeda S, Kato T, Onda T, Kasamatsu T, Fujiwara Y. Clinical characteristics and outcomes of women with stage IV endometrial cancer. Med Oncol. 2010 Dec;27(4):1371-7.
32. 谷岡真樹、勝俣範之「がん薬物療法の基本的考え方、抗悪性腫瘍薬の分類」抗悪性腫瘍薬コンサルトブック 2-11, 2010
33. 城戸秀倫、勝俣範之「がん」看護データバンク 中山書店 56-61, 2010
34. 本田和典、勝俣範之「遅発性嘔吐」Oncology Nursing vol4 No.2 17-18, 2010
35. 植原貴史、勝俣範之 CPT-11 による重症下痢に対して、ロペラミド大量療法が奏効した 1 例 腫瘍内科,5(3):353-358, 2010
36. 小野麻紀子、勝俣範之 「乳がん患者を診る」レジデントノート Vol12, No.9, 1519-1524, 2010
37. 「がん診療レジデントマニュアル第 5 版」医学書院 2010 年 6 月 15 日
38. 田部宏、勝俣範之 「婦人科がん」EBM がん化学療法・分子標的治療法中外医学社 398-403,2010
39. 小谷凡子、勝俣範之. 「第三相試験」がん薬物療法学. 日本臨床.2009;67:408-413.
40. 本多和典、勝俣範之. 「卵巣癌」がん薬物療法学. 日本臨床.2009;67:695-699.
41. 山口智宏、勝俣範之. 「がん薬物療法専門医のための模擬テスト 1」. 腫瘍内科.2009;3(1):132-134.
42. 平田泰三、勝俣範之. 「乳がん術後化学療法として AC 療法に引き続く毎週投与のパクリタキセル」. critical eyes.2009;30:3-4.
43. 東光久、勝俣範之. 「子宮頸がん」. Pharma Tribune.2009;1(7):22-29.
44. 橋本淳、勝俣範之. 「第 47 回日本癌治療学会関連特集 婦人科癌」. Medicament News 1992.2009:11-13.
45. 原野謙一、勝俣範之. 「婦人科癌化学療法クリニカルパス」婦人科癌化学療法ポケットマニュアル.2009. メディカルビュー社.
46. Yonemura M, Katsumata N,

- Hashimoto H, Satake S, Kaneko M, Kobayashi Y, Takashima A, Kato Y, Takeuchi M, Fujiwara Y, Yamamoto H, Hojo T. Randomized Controlled Study Comparing Two Doses of Intravenous Granisetron (1 and 3 mg) for Acute Chemotherapy-induced Nausea and Vomiting in Cancer Patients: A Non-inferiority Trial. *Jpn J Clin Oncol*.2009.
47. Iwasa S, Ando M, Ono M, Hirata T, Yunokawa M, Nakano E, Yonemori K, Kouno T, Shimizu C, Tamura K, Katsumata N, Fujiwara Y. Relapse with Malignant Transformation After Chemotherapy for Primary Mediastinal Seminoma: Case Report. *Jpn J Clin Oncol*.2009.
48. himozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, Ohsumi S, Makino H, Mukai H, Katsumata N, Sunada Y, Watanabe T, Hausheer FH. Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. *Support Care Cancer*.2009.
49. Katsumata N, Watanabe T, Minami H, Aogi K, Tabei T, Sano M, Masuda N, Andoh J, Ikeda T, Shibata T, Takashima S. Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802). *Ann Oncol*.2009;20(7):1210-5.
50. Iura A, Katsumata N, Kouno T, Shimizu C, Ando M, Fujiwara Y. Outpatient management of low-risk febrile patients on paclitaxel and carboplatin for ovarian cancer. *Int J Gynaecol Obstet*. Epub 2009;105(3):261-2.
51. Ono M, Ando M, Yunokawa M, Nakano E, Yonemori K, Matsumoto K, Kouno T, Shimizu C, Tamura K, Katsumata N, Fujiwara Y. Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer. *Int J Clin Oncol*. Epub 2009;14(1):48-52.
52. Matsumoto K, Shimizu C, Arao T, Andoh M, Katsumata N,

- Kohno T, Yonemori K, Koizumi F, Yokote H, Aogi K, Tamura K, Nishio K, Fujiwara Y. Identification of predictive biomarkers for response to trastuzumab using plasma FUCA activity and N-glycan identified by MALDI-TOF-MS. *J Proteome Res.*2009;8(2):457-62.
53. Noriyuki Katsumata, Makoto Yasuda, Fumiaki Takahashi, Seiji Isonishi, Toshiko Jobo, Daisuke Aoki, Hiroshi Tsuda, Toru Sugiyama, hoji Kodama, Eizo Kimura, Kazunori Ochiai, and Kiichiro Noda, for the Japanese Gynecologic Oncology Group A Randomised Phase III Trial of “Dose-dense” Weekly Paclitaxel in Combination with Carboplatin for Advanced Ovarian Cancer. *Lancet.*2009;374:1331-1338.
- (分担研究者：鈴木光明)
1. Wang D, Saga Y, Mizukami H, Sato N, Nonaka H, Fujiwara H, Takei Y, Machida S, Takikawa O, Ozawa K, Suzuki M. : Indoleamine-2,3-dioxygenase, an immunosuppressive enzyme that inhibits natural killer cell function, as a useful target for ovarian cancer therapy. *Int J Oncol* 40:929-934,2012.
 2. Nagashima S, Yagyu H, Takahashi N, Kurashina T, Takahashi M, Tsuchita T, Tazoe F, Wang XL, Bayasgalan T, Sato N, Okada K, Nagasaka S, Gotoh T, Kojima M, Hyodo M, Horie H, Hosoya Y, Okada M, Yasuda Y, Fujiwara H, Ohwada M, Iwamoto S, Suzuki M, Nagai H, Ishibashi S. Depot-specific expression of lipolytic genes in human adipose tissues — Association among CES1 expression, triglyceride lipase activity and adiposity. *J Atheroscler Thromb* 18:190-199,2011.
 3. Fujiwara H, Suzuki M [©], Yoshinari T, Shiiya K. : Free school-based vaccination with HPV vaccine in a Japanese city. *Vaccine* 29:6441-6442,2011.
 4. Takahashi K, Saga Y, Mizukami H, Takei Y, Urabe M, Kume A, Suzuki M, Ozawa K. Development of a mouse model for lymph node metastasis with endometrial cancer. *Cancer Sci* 102:2272-2277, 2011.
 5. Fujiwara K, Aotani E, Hamano T, Nagao S, Yoshikawa H, Sugiyama T, Kigawa J, Aoki D,

- Katsumata N, Takeuchi M, Suzuki M: A Randomized Phase II/III Trial of 3 Weekly Intraperitoneal versus Intravenous Carboplatin in Combination with Intravenous Weekly Dose-Dense Paclitaxel for Newly Diagnosed Ovarian, Fallopian Tube and Primary Peritoneal Cancer. *Jpn J Clin Oncol*. 2010 Oct 11. [Epub ahead of print]
6. Yoshihara k, Tajima A, Yahata T, Kodama S, Fujiwara H, Suzuki M, Onishi Y, Hatae M, Sueyoshi K, Fujiwara H, Kudo Y, Kotera K, Masuzaki H, Tashiro H, Katabuchi H, Inoue I, Tanaka K. : Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets. *PLOS ONE* 5:e9615,2010.
 7. Nonaka H, Saga Y, Fujiwara H, Akimoto H, Yamada A, Kagawa S, Takei Y, Machida S, Takikawa O, Suzuki M. Indoleamine 2,3-dioxygenase promotes peritoneal dissemination of ovarian cancer through inhibition of natural killer cell function and angiogenesis promotion. *Int J Oncol* 38:113-20,2011.
 8. Fujiwara H, Ogawa S, Motoyama M, Takei Y, Machida S, Taneichi A, Ohwada M, Suzuki M. Frequency and characteristics of endometrial carcinoma and atypical hyperplasia detected on routine infertility investigations in young women : a report of six cases. *Human Reprod*.2009; 24:1045-1050.
 9. Shimada M, Kigawa J, Ohishi Y, Yasuda M, Suzuki M, Hiura M, Nishimura R, Tabata T, Sugiyama T, Kaku T. Clinicopathological characteristics of mucinous adenocarcinoma of the ovary. *Gynecol Oncol*.2009;113:331-4.
 10. Yoshihara K, Tajima A, Komata D, Yamamoto T, Kodama S, Fujiwara H, Suzuki M, Onishi M, Hatae M, Sueyoshi K, Fujiwara H, Kudo Y, Inoue I, Tanaka K. Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis. *Cancer Sci*.2009;100:1421-1428.
 11. Takahashi K, Saga Y, Mizukami

H, Takei Y, Machida S, Fujiwara H, Ozawa K, Suzuki M. Cetuximab inhibits growth, peritoneal dissemination, and lymph node and lung metastasis of endometrial cancer, and prolongs host survival. *Int J Oncol*.2009;35:725-729.

12. Wada T, Yamashita Y, Saga Y, Takahashi K, Koinuma K, Choi Y-L, Kaneda R, Fujiwara S, Soda M, Watanabe H, Kurashima K, Hatanaka H, Enomoto M, Takada S, Mano H, Suzuki M. Screening for genetic abnormalities involved in ovarian carcinogenesis using retroviral expression libraries. *Int J Oncol*.2009;35:973-976.

(分担研究者:竹内正弘)

1. Fujiwara K, Aotani E, Hamano T, Nagao S, Yoshikawa H, Sugiyama T, Kigawa J, Aoki D, Katsumata N, Takeuchi M, Suzuki M. A Randomized Phase II/III Trial of 3 Weekly Intraperitoneal versus Intravenous Carboplatin in Combination with Intravenous Weekly Dose-Dense Paclitaxel for Newly Diagnosed Ovarian, Fallopian Tube and Primary Peritoneal Cancer. *Jpn J Clin Oncol*. 2010 Oct 11. [Epub ahead

of print]

2. H. Taniguchi, M. Ebina, Y. Kondoh, T. Ogura, A. Azuma, M. Suga, Y. Taguchi, H. Takahashi, K. Nakata, A. Sato, Takeuchi M, G. Raghu, S. Kudoh, T. Nukiwa, and Pirfenidone Clinical Study Group in Japan. Pirfenidone in idiopathic pulmonary fibrosis: A phase III clinical trial in Japan. *Eur Respir J*. 2010;35: 821-829.

3. Takeuchi M. Prediction of an outcome using trajectories estimated from a linear mixed model. *J of Bioharmaceutical Statistics*.2009;19(5):779-790.

4. Takeuchi M. Design, statistical analysis and sample size calculation of a phase I/II/III study of linagliptin versus voglibose and placebo. *Trials*.2009;10.

5. Takeuchi M. Predicting steady-state HbA1c responses to sitagliptin in patients with type 2 diabetes mellitus, Diabetes. Obesity and Metabolism.2009;11:813-818.
*PMID: 19390555

6. Takeuchi M. Reasons for response differences seen in the V15-32,